Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aronex Pharma (ARNX) -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (275)	8/5/1999 5:45:00 PM
From: JOEBT1	Read Replies (1) \| Respond to of 320

ARNX IS A SOLID COMPANY ARNX is in a partrnership with Abbot on Nyotran and about to file an NDA after completing PIII. Abbot gave ARNX 9.9 million in the first half of '99 for meeting PIII milestones. Abbot has paid a total of 14.7M and bought 3M in ARNX stock. ARNX has 29M in cash. Atragen is the drug involved in the announced FDA delay. Based on my conversation with IR this AM the company is totally in the dark on the FDA delay. They had passed all MFG and laboratory inspections. The FDA has had the NDA filing since Dec '98 and had scheduled the Advisory meeting in July. Atragen is being tested in other cancer applications as well. Arnx also has a promising drug , Platar which is in PII with promising results. The info in the SCAM ALERT you posted is probably generated by shorts IMO.